Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.44 |
| ▸ | MLYCD | O95822 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997930 | 0.90 | PTGES (0.49) | PTGESMLYCDPPARDGCKPPARG | |
| SCHEMBL3571641 | 0.85 | PTGES (0.53) | PTGESMLYCDPOLBSCN9AKDM4E | |
| SCHEMBL333994 | 0.83 | PTGES (0.37) | PTGESPOLBSCN9AKDM4EL3MBTL1 | |
| SCHEMBL3582187 | 0.81 | PTGES (0.67) | PTGESPPARDPPARG | |
| SCHEMBL3001790 | 0.78 | KDM4E (0.40) | PTGESPOLBSCN9AKDM4EL3MBTL1 | |
| SCHEMBL2997500 | 0.78 | KDM4E (0.40) | PTGESPOLBSCN9AKDM4EL3MBTL1 | |
| SCHEMBL3008051 | 0.77 | KDM4E (0.39) | PTGESPOLBSCN9AKDM4EL3MBTL1 | |
| SCHEMBL3006452 | 0.77 | KDM4E (0.39) | PTGESMLYCDPOLBSCN9AKDM4E | |
| SCHEMBL3001004 | 0.77 | KDM4E (0.39) | PTGESPOLBSCN9AKDM4EL3MBTL1 | |
| SCHEMBL3000835 | 0.77 | KMT2A (0.43) | PTGESKDM4EL3MBTL1SMN1; SMN2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | disclosed |
| EP-1841736-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006077367-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMATION | BIOLIPOX AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | PTGES 33/4885MLYCD 1376/4885POLB 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.